Virtual Incision Corp. announced FDA approval of an Investigational Device Exemption supplement for its final stage clinical study of the MIRA Platform for bowel resection procedures.
According to a company press release, MIRA is the first-of-its-kind, miniaturized robotic-assisted surgery (RAS) platform, which offers the benefits of RAS without the inefficiencies of traditional robotics. The platform received favorable interim trial safety profile reports.